Morgan Stanley upgraded Takeda (TAK) to Overweight from Equal Weight with a price target of 5,500 yen, up from 4,300 yen. The company does not have any big patents expiring soon that would significantly affect its earnings, and has established a stable portfolio with plasma-derived therapies, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda Canada says Health Canada expands marketing authorization for HyQvia
- Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
- Harmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakeda
- Takeda Announces Share Repurchase Program for February 2025
- Takeda announces EMA approval for Takhzyro two mL pre-filled pen option